Evidence map›Paper›PMID 35544650›Full record

ArticleJCO oncology practice2022

Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis.

Nahomy Ledesma Vicioso, Diana Lin, Daniel R Gomez, Jonathan T Yang, Nancy Y Lee, Andreas Rimner, Yoshiya Yamada, Michael J Zelefsky, Noah S Kalman, Charles E Rutter and 14 more

Abstract read
In one paragraph

Article in JCO oncology practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Increasing Diversity of Patients in Radiation Oncology Clinical Trials.International journal of radiation oncology, biology, physics · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Nahomy Ledesma ViciosoDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-2294-3352
Diana LinDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Daniel R GomezDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Jonathan T YangDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Nancy Y LeeDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-3044-9522
Andreas RimnerDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-1214-3856
Yoshiya YamadaDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Michael J ZelefskyDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Noah S KalmanDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.ORCID 0000-0003-1299-3014
Charles E RutterHartford HealthCare Cancer Institute, Hartford, CT.
Rupesh R KotechaDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.ORCID 0000-0001-6927-0402
Minesh P MehtaDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.ORCID 0000-0002-4812-5713
Joseph E PanoffDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
Michael D ChuongDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.ORCID 0000-0001-8328-7518
Andrew L SalnerHartford HealthCare Cancer Institute, Hartford, CT.ORCID 0000-0002-3145-2953
Jamie S OstroffDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-2671-5680
Lisa C DiamondImmigrant Health and Cancer Disparities Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-2175-6224
Noah J MathisDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-1125-6282
Oren CahlonDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
David G PfisterDepartment of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Zhigang ZhangDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Fumiko ChinoDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-0498-488X
Jillian TsaiDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-0400-2655
Erin F GillespieDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-1386-1542

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Leveraging implementation science to accelerate adoption of shorter-course radiation for breast and prostate cancerK08CA252640 · NCI · UNIVERSITY OF WASHINGTON · PI GILLESPIE, ERIN FAYE · 2020 to 2025
$1.3M
NCI NIH HHS K08 CA252640NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeCommunity-academic partnerships have the potential to improve access to clinical trials for under-represented minority patients who more often receive cancer treatment in community settings. In 2017, the Memorial Sloan Kettering (MSK) Cancer Center began opening investigator-initiated clinical trials in radiation oncology in targeted community-based partner sites with a high potential to improve diverse population accrual. This study evaluates the effectiveness of a set of implementation strategies for increasing overall community-based enrollment and the resulting proportional enrollment of Hispanic patients on trials on the basis of availability in community-based partner sites.

methodsAn interrupted time series analysis evaluating implementation strategies was conducted from April 2018 to September 2021. Descriptive analysis ofHispanic enrollment on investigator-initiated randomized therapeutic radiation trials open at community-based sites was compared with those open only at themain academic center.

resultsOverall, 84 patients were enrolled in clinical trials in the MSK Alliance, of which 48 (56%) identified as Hispanic. The quarterly patient enrollment pre- vs postimplementation increased from 1.39 (95% CI, -3.67 to 6.46) to 9.42 (95% CI, 2.05 to 16.78; P5 .017). In the investigator-initiated randomized therapeutic radiation trials open in the MSK Alliance, Hispanic representation was 11.5% and 35.9% in twometastatic trials and 14.2% in a proton versus photon trial. Inmatched trials open only at the main academic center, Hispanic representation was 5.6%, 6.0%, and 4.0%, respectively.

conclusionA combination of practice-level and physician-level strategies implemented at community-based partner sites was associated with increased clinical trial enrollment, which translated to improved Hispanic representation. This supports the role Q:2 of strategic community-academic partnerships in addressing disparities in clinical trial enrollment.

Indexed as

Clinical Trials as TopicHispanic or LatinoPatient ParticipationHumansInterrupted Time Series AnalysisPhysiciansResearch Personnel

Identifiers

PMID35544650
PMCPMC10166438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.